The BioPharm Brief: Gene Therapy Reform, Cancer Trial Endpoints, and a $1.2B Rare Disease Deal

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

First up today, the U.S. Food and Drug Administration has issued draft guidance aimed at making rare disease gene therapy development more efficient. The proposal would allow developers to rely more on established scientific knowledge and previously generated data when preparing regulatory submissions. The idea is to reduce redundancy in early development while still maintaining safety and evidentiary standards, particularly for ultra-rare conditions where patient populations are limited. The guidance also emphasizes the use of manufacturing and platform-based knowledge from related products.

In oncology news, updated phase 3 trial designs are drawing attention for incorporating dual survival endpoints in studies of izalontamab brengitecan, being evaluated in triple-negative breast cancer and esophageal cancer. These trials are designed to assess both overall survival and progression-free survival as key measures, reflecting a broader trend in oncology toward more comprehensive endpoints in late-stage development. The approach aims to capture both durability of response and overall clinical benefit in difficult-to-treat cancers.

Finally, Eli Lilly has entered into a licensing agreement with Hanmi Pharmaceutical for sonefpeglutide, a long-acting GLP-2 receptor agonist in development for short bowel syndrome. The deal is valued at up to $1.2 billion, including upfront and milestone payments, with Hanmi retaining rights in South Korea. The therapy is being evaluated in Phase 2 studies and is designed to improve intestinal absorption in patients with reduced functional small bowel.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key Insights

• FDA draft guidance could reduce redundancy in rare disease gene therapy submissions.
• Oncology Phase 3 trials are increasingly incorporating dual survival endpoints.
• Lilly’s $1.2B deal highlights continued licensing activity in rare gastrointestinal diseases.